Street View: Eli Lilly's obesity drug pipeline seen powering sustained growth

Eli Lilly LLY.N said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a significantly accelerated approval review

Median PT of 32 brokerages covering the stock is $950 - LSEG data

SLIMMING DOWN, BULKING UP

Truist Securities ("buy," PT: $1,038) says there is strong global appetite for weight loss therapies, "that we believe will continue on a global level"

J.P.Morgan ("overweight") sees LLY's valuation as increasingly compelling for a business generating low-teens topline and high-teens EPS growth through at least the early 2030s

Danni Hewson, head of financial analysis at AJ Bell, says "the use of weight-loss drugs has exploded and the potential market is massive, particularly if the company can get its oral weight-loss pill fast-tracked for approval in the U.S."

Morgan Stanley ("overweight," PT: $1,069) calls Lilly a "generational opportunity" because it's launching multiple high-impact drugs such as Orforglipron and Tirzepatide that could transform treatment in obesity, diabetes, and Alzheimer's, driving massive revenue growth and margin expansion